Furthermore, Dasatinib treatment can restore the aforementioned Cetuximab sensitivity of EGFR-positive breast cancers, and also overcome BRAF inhibitor resistance in melanoma cells [134]. The gene discussed is EGFR; the disease is breast carcinoma.